It should be noted that quizartinib has been approved in Europe by the European Medicines Agency as a maintenance therapy after transplant in FLT3-ITD-positive AML, but it has not been approved for this indication by the U.S. Food and Drug Administration (FDA). This evidence concerns the gene FLT3 and acute myeloid leukemia.